



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of
Nagarajan, et. al.

Attorney Docket No. 3321/US

Serial No. 09/881,913

Group Art Unit: 1623

Filed: 06/15/01

Examiner: Unknown

RECEIVED
SEP 20 2002
TECH CENTER 1600/2900

For: Heteroarylalkanoic Acids as Integrin Receptor Antagonists

Assistant Commissioner of Patents
Washington, D.C. 20231

SIR:

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance with the duty of disclosure set forth in 37 C.F.R. 1.56, applicants submit herewith a document cited on the attached Form PTO 1449. Applicants direct the Examiner to the related application(s) for documents previously submitted. Applicants respectfully request that the Examiner consider and enter the document cited on the enclosed Form PTO 1449 into the file of the above-identified application. Applicants also request an indication of the same by return of the Form PTO 1449 being initialed and dated by the Examiner.

Please charge the fee of \$180.00 as required by 37 C.F.R. § 1.17(p) to Deposit Account No. 19-1025. No additional fees are believed due to ensure consideration of the attached documents by the Examiner. However, if any additional fees are required or an overpayment of fees made, the Commissioner is hereby authorized to debit or credit our Deposit Account No. 19-1025, as necessary.

09/19/2002 SZWDIE1 00000099 191025 09881913

01 FC:126 180.00 CH

Respectfully submitted,

Rachel A. Polster, Agent
Registration No. 47,004
(314) 694-7354 (St. Louis)

Pharmacia Corporation
Corporate Patent Department
800 North Lindbergh Boulevard – O4E
St. Louis, MO 63167